They found that the urine-based NMP22 BladderChek Test is cost effective for screening high risk populations
based on its cost and accuracy in detecting bladder cancer.
Matritech (Amex: MZT), a leading developer and marketer of protein-based diagnostic products for the early detection of cancer, announced today that independent investigators have reported that certain tests, such as the NMP22(R) BladderChek(R) Test, could save lives and reduce expense when screening high risk populations
for bladder cancer.
According to the final Jones criteria, Turkey is compatible with moderate and high risk populations
as a result of regional screenings performed in terms of ARF and rheumatic heart disease.
Modernization and construction of adequate technical infrastructure enabling comprehensive and continuous monitoring of cerebral function, and cardiovascular system at risk populations
Use in such high risk populations
may allow rapid regulatory and market acceptance.